{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yu M"],"funding":["NIA NIH HHS","R.A.C.E. Charities","National Cancer Institute","NCI NIH HHS","Cottrell Family Fund","Huntsman Cancer Foundation","Listwin Family Foundation"],"pagination":["1146-1152"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10529338"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(9)"],"pubmed_abstract":["<h4>Background</h4>Individuals with adenomatous colorectal polyps undergo repeated colonoscopy surveillance to identify and remove metachronous adenomas. However, many patients with adenomas do not develop recurrent adenomas. Better methods to evaluate who benefits from increased surveillance are needed. We evaluated the use of altered EVL methylation as a potential biomarker for risk of recurrent adenomas.<h4>Methods</h4>Patients with ≥1 colonoscopy had EVL methylation (mEVL) measured with an ultra-accurate methylation-specific droplet digital PCR assay on normal colon mucosa. The association between EVL methylation levels and adenoma or colorectal cancer was evaluated using three case/control definitions in three models: unadjusted (model 1), adjusting for baseline characteristics (model"],"journal":["Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"],"pubmed_title":["Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas."],"pmcid":["PMC10529338"],"funding_grant_id":["R50CA233042","R50 CA233042","R01CA211705","R01 CA207371","U2C CA271902","UO1AG077920","RO1CA220004","U54 CA274374","UO1CA152756","UO1CA152753","UO1CA206110","U54CA274374","U01 CA206110","U01 CA152756","R01 CA211705","U01 CA152753","RO1CA189184","R01 CA220004","U01 AG077920","RO1CA207371"],"pubmed_authors":["Toriola AT","Gigic B","Yu M","Baker KK","Ose J","Shibata D","Dzubinski LA","Vickers K","Schneider M","Carter KT","Schoen RE","Siegel EM","Figueiredo JC","Grady WM","Cohen SA","Li CI","Wang T","Krane M","Redman MW","Ulrich CM"],"additional_accession":[]},"is_claimable":false,"name":"Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas.","description":"<h4>Background</h4>Individuals with adenomatous colorectal polyps undergo repeated colonoscopy surveillance to identify and remove metachronous adenomas. However, many patients with adenomas do not develop recurrent adenomas. Better methods to evaluate who benefits from increased surveillance are needed. We evaluated the use of altered EVL methylation as a potential biomarker for risk of recurrent adenomas.<h4>Methods</h4>Patients with ≥1 colonoscopy had EVL methylation (mEVL) measured with an ultra-accurate methylation-specific droplet digital PCR assay on normal colon mucosa. The association between EVL methylation levels and adenoma or colorectal cancer was evaluated using three case/control definitions in three models: unadjusted (model 1), adjusting for baseline characteristics (model","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2025-04-26T04:12:31.261Z","creation":"2025-04-06T11:02:28.474Z"},"accession":"S-EPMC10529338","cross_references":{"pubmed":["37294695"],"doi":["10.1158/1055-9965.EPI-22-1020","10.1158/1055-9965.epi-22-1020"]}}